Using biomarkers to choose second-line treatment for atopic dermatitis
Studies whether genetic and blood markers can help pick treatment for atopic dermatitis.
Key facts
- Who runs it
- Hospital Universitario La Paz
- Where
- Madrid, SpainSee the site
- Trial code
- Registry title
- Optimization of atopic dermatitis treatment that requires second-line systemic therapy through multiomic predictive models of treatment response (DermAtOmics-II)
- Status
- Recruiting
- Phase
- Phase 4
- Started
- 25 Sept 2023
- Planned end
- 1 Sept 2025
- Type of study
- Interventional
- Record updated
- 20 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with moderate-severe atopic dermatitis who are about to start, or are already taking, a second-line systemic treatment.
- Age
- Not stated. Children can join with a parent or guardian's consent; minors over 11 must also agree.
- Sex
- All sexes can join.
- Disease stage
- Moderate-severe atopic dermatitis.
- Earlier treatment
- Cohort 1: about to start second-line systemic treatment. Cohort 2: already taking second-line systemic therapy. Anyone who took an investigational drug within 60 days cannot join.
Main reasons for not taking part
- Took an investigational drug within 60 days before the study drug
- Any condition that prevents or interferes with following the protocol
- Women who can have children must have a negative urine pregnancy test at Screening and Day 0
- Women who can have children must agree not to become pregnant and to use highly effective contraception or abstinence
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Cohort 1: Subjects diagnosed with moderate-severe atopic dermatitis who are going to receive second-line systemic treatment; Cohort 2: Subjects diagnosed with moderate-severe atopic dermatitis who are already receiving second-line systemic therapy at the time of selection
- Participants must be willing and able to provide written informed consent prior the initiation of any study procedures
- For children, parent/legal guardian must provide written informed consent. If age >11 years old, the minor must give assent
- Participant is willing and able to adhere to the procedures specified in this protocol
Who cannot take part
- Any investigational drug within 60 days prior to study drug administration
- Any condition or situation precluding or interfering the compliance with the protocol
- Women of childbearing potential must have a negative urine pregnancy test at Screening and Day 0
- Women of childbearing potential must commit not to become pregnant. They must be willing to use highly effective contraceptive methods or have practiced sexual abstinence during the study
Where in Spain
- Hospital Universitario La PazMadrid, SpainTaking people
About the trial
What the trial wants to find out
1. To identify genetic, biochemical and immunological biomarkers that allow for the selection of the most appropriate therapeutic alternative in each patient and the development of a prediction model using these biomarkers. 2. To optimize therapy in patients with AD requiring second-line systemic treatment by developing predictive response models (PBPK/PK/PD) that incorporate genetic, immunological, biochemical, clinical, and demographic variables.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Optimization of atopic dermatitis treatment that requires second-line systemic therapy through multiomic predictive models of treatment response (DermAtOmics-II)
- Plain-language title
- Using biomarkers to choose second-line treatment for atopic dermatitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 20 August 2025